Plant Name: Sarcococca saligna
Taxonomic Information:
Plant ID: NPO27888
Plant Latin Name: Sarcococca saligna
Taxonomy Genus: Sarcococca
Taxonomy Family: Buxaceae
Plant External Links:
NCBI TaxonomyDB:
153583
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
India; China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; ADRA2B; | |
| BCHE; ACHE; | |
| ESR1; | |
| HIF1A; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.280E-12 | 2.786E-08 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.214E-11 | 3.059E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.832E-10 | 9.972E-07 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 7.325E-10 | 1.994E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 7.325E-10 | 1.994E-06 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.325E-10 | 1.994E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.023E-09 | 8.413E-06 | BCHE, CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.024E-08 | 1.394E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.024E-08 | 1.394E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.255E-08 | 1.607E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.017E-08 | 4.166E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 2.076E-07 | 1.614E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.222E-07 | 2.150E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 3.538E-07 | 2.266E-04 | ACHE, BCHE |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.739E-07 | 4.758E-04 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.061E-06 | 5.247E-04 | CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.084E-06 | 5.247E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.084E-06 | 5.247E-04 | CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.131E-06 | 9.282E-04 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 6.145E-06 | 2.433E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.588E-05 | 5.402E-03 | CYP1A2, CYP2C9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.289E-08 | 1.265E-06 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.907E-08 | 1.265E-06 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.977E-07 | 6.376E-06 | CYP2C9, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 7.059E-06 | 5.647E-05 | CYP2C9, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.423E-05 | 9.107E-05 | CYP2C9, CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.190E-04 | 6.348E-04 | ADRA2C, ADRA2B, ADRA2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 5.270E-04 | 2.142E-03 | ADRA2C, ADRA2B, ADRA2A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.354E-04 | 2.142E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.978E-03 | 7.013E-03 | CYP2C9, CYP2D6 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.192E-03 | 7.013E-03 | ESR1, HIF1A |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.997E-03 | 8.718E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
